EYPT EyePoint Pharmaceuticals
- 8.000
- +0.010+0.13%
- 7.780
- -0.220-2.75%
EyePoint Pharmaceuticals News
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15
Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments
EyePoint Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)
Optimistic 'Buy' Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Prospects
EyePoint Pharmaceuticals Earns Buy Rating on Duravyu's Promising Efficacy and Safety Profile
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals Analyst Ratings
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Phase 3 Trials and FDA Alignment
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and Trials
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future Prospects
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating
EyePoint Pharmaceuticals Analyst Ratings
Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38
Maintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study Setback
Analysis
Price Target
No Data
No Data